Schrödinger, Inc. reported $259M of revenue over the trailing twelve months, +8.9% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $259M (to Q2 2026). Net income: −$54M, trailing twelve months to Q2 2026. Free cash flow: −$130M, trailing twelve months to Q2 2026. Operating margin: −65%, trailing twelve months to Q2 2026.

SDGRSchrödinger, Inc.

Healthcare

$27.27+40% 1Y

$27.27

$11.0752 weeks$32.59

SDGR as reported

Schrödinger, Inc. reported $259M of revenue over the trailing twelve months, +8.9% on the year before. 10 reported series are charted on this page, each one as filed.

$259M

Revenue, trailing twelve months · to Q2 2026 · +8.9% against the twelve months before

Net income: −$54M
Net income · −70% year on year · trailing twelve months to Q2 2026
Free cash flow: −$130M
Free cash flow · −635% year on year · trailing twelve months to Q2 2026
Operating margin: −65%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for SDGR, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$259M	+8.9%	Q2 2026
Net income	−$54M	−70%	Q2 2026
EPS	−$0.74	−70%	Q2 2026
Gross margin	56%	n/a	Q2 2026
Operating margin	−65%	n/a	Q2 2026
Net margin	−29%	n/a	Q2 2026
ROE	−33%	n/a	Q2 2026
ROA	−16%	n/a	Q2 2026
Free cash flow	−$130M	−635%	Q2 2026
P/E	94.3	n/a	Q4 2023 · 10 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.